No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology

Human Reproduction

Volumn 32, Issue 1, 2017, Pages 125-132

  Tatsumi, T ^a,b   Jwa, S C ^a,c   Kuwahara, A ^d   Irahara, M ^d   Kubota, T ^b   Saito, H ^a  

^a NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c SORA No MORI Clinic   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

congenital anomaly; letrozole; mild ovarian stimulation; neonatal outcome; ovulation induction method; pregnancy outcome

Indexed keywords

LETROZOLE; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ADVERSE OUTCOME; ARTICLE; BLASTOCYST; CARDIOVASCULAR MALFORMATION; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONGENITAL MALFORMATION; DRUG SAFETY; ECTOPIC PREGNANCY; FEMALE; HUMAN; IN VITRO FERTILIZATION; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LARGE FOR GESTATIONAL AGE; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM MALFORMATION; NEONATAL OUTCOME; NEWBORN; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; PREGNANCY TERMINATION; PREMATURE LABOR; RETROSPECTIVE STUDY; RISK REDUCTION; SINGLE EMBRYO TRANSFER; SPONTANEOUS ABORTION; STILLBIRTH; DRUG INDUCED MALFORMATION; MATERNAL AGE; PROCEDURES; RISK;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ADULT; AROMATASE INHIBITORS; FEMALE; FERTILIZATION IN VITRO; HUMANS; INFANT, NEWBORN; MATERNAL AGE; NITRILES; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; RISK; TRIAZOLES;

EID: 85011285149     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dew280     Document Type: Article

References (33)

1. Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. Fertil Steril 2007; 88: 657-664.
2. Biljan MM, Hemmings R, Brasard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril 2005; 84: O-231, Abstract 1033.
3. Casals G, Ordi J, Creus M, Fabregues F, Carmona F, Casamitjana R, Balasch J. Osteopontin and alphavbeta3 integrin as markers of endometrial receptivity: the effect of different hormone therapies. Reprod Bio Med Online 2010; 21: 349-359.
4. Diamond M, Legro R, Coutifiaris C, RAlvero, Robinson R, Zhang H. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med 2015; 373: 1230-1240.
5. Eftekhar M, Mohammadian F, Davar R, Pourmasumi S. Comparison of pregnancy outcome after letrozole versus clomiphene treatment for mild ovarian stimulation protocol in poor responders. Iran J Reprod Med 2014; 12: 725-730.
6. Fedder J, Loft A, Parner ET, Rasmussen S, Pinborg A. Neonatal outcome and congenital malformations in children born after ICSI with testicular or epididymal sperm: a controlled national cohort study. Hum Reprod 2013; 28: 230-240.
7. Ganesh A, Chauhan N, Das S, Chakravarty B, Chaudhury K. Endometrial receptivity markers in infertile women stimulated with letrozole compared with clomiphene citrate and natural cycles. Syst Biol Reprod Med 2014; 60: 105-111.
8. Gill SK, Moretti M, Koren G. Is the use of letrozole to induce ovulation teratogenic? Can Family Phys 2008; 54: 353-354.
9. Goldrat O, Gervy C, Englert Y, Delbaere A, Demeestere I. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Hum Reprod 2015; 30: 2184-2189.
10. Hirahara F. Monitoring of of birth defects in Japan. Grants-in-Aid for Sci Res Jpn 2013 (in Japanese).
11. Hu YJ, Chen YZ, Zhu YM, Huang HF. Letrozole stimulation in endometrial preparation for cryopreserved-Thawed embryo transfer in women with polycystic ovarian syndrome: a pilot study. Clin Endocrinol 2014; 80: 283-289.
12. Itabashi K, Fujimura M, Kusuda S, Tamura M, Hayashi T, Takahashi T. The new standard of birth weight for gestational age. J Jpn Pediatr Soc 2010; 114: 1271-1293 (in Japanese).
13. Kar S. Current evidence supporting ?letrozole? for ovulation induction. J Hum Reprod Sci 2013; 6: 93-98.
14. Lee VC, Chan CC, Ng EH, Yeung WS, Ho PC. Sequential use of letrozole and gonadotrophin in women with poor ovarian reserve: a randomized controlled trial. Reprod BioMed Online 2011; 23: 380-388.
15. Lessey BA, Castelbaum AJ, Sawin SW, Sun J. Integrins as markers of uterine receptivity in women with primary unexplained infertility. Fertil Steril 1995; 63: 535-542.
16. Li SJ, Zhang YJ, Chai XS, Nie MF, Zhou YY, Chen JL, Tao GS. Letrozole ovulation induction: an effective option in endometrial preparation for frozen-Thawed embryo transfer. Arch Gynecol Obstet 2014; 289: 687-693.
17. Matsunaga R, Ochi M. The relationship between follicle size and embryo developmental competence in letrozole stimulation cycles. J Fertili Implant 2013; 30: 277-280 (in Japanese).
18. Miller PB, Parnell BA, Bushnell G, Tallman N, Forstein DA, Higdon HL, Kitawaki J, Lessey BA. Endometrial receptivity defects during IVF cycles with and without letrozole. Hum Reprod 2012; 27: 881-888.
19. Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 2005; 192: 381-386.
20. Novartis Pharmaceuticals Canada Inc. Health Canada Endorsed Important Safety Information on Femara (letrozole). 2005, 3.
21. Palomba S. Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2015; 100: 1742-1747.
22. Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H, Tarlatzis B. Aromatase inhibitors in stimulated IVF cycles. Reprod Biol Endocrinol 2011; 9: 85.
23. Pelkonen S, Hartikainen AL, Ritvanen A, Koivunen R, Martikainen H, Gissler M, Tiitinen A. Major congenital anomalies in children born after frozen embryo transfer: a cohort study 1995-2006. Hum Reprod 2014; 29: 1552-1557.
24. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2003; 67: 193-201.
25. Reefhuis J, Honein MA, Schieve LA, Correa A, Hobbs CA, Rasmussen SA. Assisted reproductive technology and major structural birth defects in the United States. Hum Reprod 2009; 24: 360-366.
26. Requena A, Herrero J, Landeras J, Navarro E, Neyro JL, Salvador C, Tur R, Callejo J, Checa MA, Farré M, et al. Use of letrozole in assisted reproduction: a systematic review and meta-Analysis. Hum Reprod Update 2008; 14: 571-582.
27. Saito H, Kubota T, Kuwahara A. Committee of Japanese ART Registry. Annual report of ART registry of Japan for cycles reported in 2013. Acta Obstet Gynaecol Jpn 2015; 67: 2077-2121 (in Japanese).
28. Sharma S, Ghosh S, Singh S, Chakravarty A, Ganesh A, Rajani S, Chakravarty BN. Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PLoS One 2014; 9: e108219.
29. Shozu M. Aromatase inhibitors for ovulation induction. J Clin Exp Med 2007; 223: 27-30 (in Japanese).
30. Shozu M, Usui H, Mitsuhashi A, Matsui H. Aromatase Inhibitors as an ovulation induction method. J Jpn Obstet Gynecol 2007; 37: 929-937 (in Japanese).
31. Teramoto S. Application of letrozole in ovulation induction. J Jpn Obstet Gynecol 2012; 29: 841-845 (in Japanese).
32. Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, Librach C, Greenblatt E, Casper RF. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006; 85: 1761-1765.
33. Velasco G, Juan A. The use of aromatase inhibitors in in vitro fertilization. Fertil Steril 2012; 98: 1356-1358.